WEKO3
アイテム
{"_buckets": {"deposit": "0578b874-aae0-4fd6-9bf1-925b95b64c4f"}, "_deposit": {"created_by": 7, "id": "143", "owners": [7], "pid": {"revision_id": 0, "type": "depid", "value": "143"}, "status": "published"}, "_oai": {"id": "oai:shonan-ums.repo.nii.ac.jp:00000143", "sets": ["1"]}, "author_link": ["421", "415", "416", "414", "413", "411", "417", "418", "419", "412", "420"], "item_10004_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "134", "bibliographicPageStart": "127", "bibliographicVolumeNumber": "79", "bibliographic_titles": [{}, {"bibliographic_title": "Human pathology", "bibliographic_titleLang": "en"}]}]}, "item_10004_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Limitations in obtaining surgically resected or biopsy samples of small cell lung cancer (SCLC) tumors make comprehensive biological analyses difficult. The loss of thyroid transcription factor 1 (TTF-1) has been associated with the aggressive behavior of non-small cell lung cancer; however, clinicopathological features of TTF-1-negative SCLC remain unclear. This study aimed to elucidate the characteristics of TTF-1-negative SCLC. We studied the associations between the expression of TTF-1 and the clinicopathological factors associated with SCLC, including survival and expression of neuroendocrine markers (synaptophysin, chromogranin A, and CD56), neuroendocrine cell-specific transcription factors (ASCL1, BRN2), a proliferation marker (Ki-67 labeling index), and an oncogene (NF1B). Formalin-fixed and paraffin-embedded sections of SCLC tumors were subjected to immunohistochemistry and quantitative reverse-transcription polymerase chain reaction analyses. In a case-control cohort matched for basic clinical factors, expression of ProGRP, synaptophysin, chromogranin A, and ASCL1 was significantly decreased in TTF-1-negative SCLC samples. In contrast, there was no significant correlation between Ki-67 labeling index and TTF-1. In a larger serial case cohort, TTF-1-negative SCLC cases were older at diagnosis, but there was no significant difference in the overall survival of patients with TTF-1-negative and TTF-1-positive SCLC. In conclusion, TTF-1-negative SCLC showed decreased neuroendocrine differentiation, and significantly worse clinical outcomes were not observed.", "subitem_description_type": "Abstract"}]}, "item_10004_description_6": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "Limitations in obtaining surgically resected or biopsy samples of small cell lung cancer (SCLC) tumors make comprehensive biological analyses difficult. The loss of thyroid transcription factor 1 (TTF-1) has been associated with the aggressive behavior of non-small cell lung cancer; however, clinicopathological features of TTF-1-negative SCLC remain unclear. This study aimed to elucidate the characteristics of TTF-1-negative SCLC. We studied the associations between the expression of TTF-1 and the clinicopathological factors associated with SCLC, including survival and expression of neuroendocrine markers (synaptophysin, chromogranin A, and CD56), neuroendocrine cell-specific transcription factors (ASCL1, BRN2), a proliferation marker (Ki-67 labeling index), and an oncogene (NF1B). Formalin-fixed and paraffin-embedded sections of SCLC tumors were subjected to immunohistochemistry and quantitative reverse-transcription polymerase chain reaction analyses. In a case-control cohort matched for basic clinical factors, expression of ProGRP, synaptophysin, chromogranin A, and ASCL1 was significantly decreased in TTF-1-negative SCLC samples. In contrast, there was no significant correlation between Ki-67 labeling index and TTF-1. In a larger serial case cohort, TTF-1-negative SCLC cases were older at diagnosis, but there was no significant difference in the overall survival of patients with TTF-1-negative and TTF-1-positive SCLC. In conclusion, TTF-1-negative SCLC showed decreased neuroendocrine differentiation, and significantly worse clinical outcomes were not observed.", "subitem_description_type": "Other"}]}, "item_10004_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "29787820", "subitem_relation_type_select": "PMID"}}]}, "item_10004_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1016/j.humpath.2018.05.009", "subitem_relation_type_select": "DOI"}}]}, "item_10004_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1532-8392", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Iida, Yuko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "411", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masuda, Shinobu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "412", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakanishi, Yoko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "413", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimizu, Tetsuo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "414", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishimaki, Haruna", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "415", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takahashi, Mai", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "416", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hikichi, Mari", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "417", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maruoka, Shuichiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "418", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Gon, Yasuhiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "419", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takahashi, Noriaki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "420", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hashimoto, Shu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "421", "nameIdentifierScheme": "WEKO"}]}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Aged", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Biomarkers, Tumor", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Case-Control Studies", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cell Differentiation", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cell Proliferation", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Female", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Humans", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Immunohistochemistry", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Lung Neoplasms", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Male", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Middle Aged", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Prognosis", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Reverse Transcriptase Polymerase Chain Reaction", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Small Cell Lung Carcinoma", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Thyroid Nuclear Factor 1", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.", "subitem_title_language": "en"}]}, "item_type_id": "10004", "owner": "7", "path": ["1"], "permalink_uri": "https://shonan-ums.repo.nii.ac.jp/records/143", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-06-01"}, "publish_date": "2020-06-01", "publish_status": "0", "recid": "143", "relation": {}, "relation_version_is_last": true, "title": ["Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers."], "weko_shared_id": -1}
Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.
https://shonan-ums.repo.nii.ac.jp/records/143
https://shonan-ums.repo.nii.ac.jp/records/1432feedbbe-d5c3-49d2-b47a-5f8730738a19
Item type | 一般雑誌記事 / Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-06-01 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Aged | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Biomarkers, Tumor | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Case-Control Studies | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Cell Differentiation | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Cell Proliferation | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Female | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Humans | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Immunohistochemistry | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Lung Neoplasms | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Male | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Middle Aged | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Prognosis | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Reverse Transcriptase Polymerase Chain Reaction | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Small Cell Lung Carcinoma | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Thyroid Nuclear Factor 1 | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Iida, Yuko
× Iida, Yuko× Masuda, Shinobu× Nakanishi, Yoko× Shimizu, Tetsuo× Nishimaki, Haruna× Takahashi, Mai× Hikichi, Mari× Maruoka, Shuichiro× Gon, Yasuhiro× Takahashi, Noriaki× Hashimoto, Shu |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Limitations in obtaining surgically resected or biopsy samples of small cell lung cancer (SCLC) tumors make comprehensive biological analyses difficult. The loss of thyroid transcription factor 1 (TTF-1) has been associated with the aggressive behavior of non-small cell lung cancer; however, clinicopathological features of TTF-1-negative SCLC remain unclear. This study aimed to elucidate the characteristics of TTF-1-negative SCLC. We studied the associations between the expression of TTF-1 and the clinicopathological factors associated with SCLC, including survival and expression of neuroendocrine markers (synaptophysin, chromogranin A, and CD56), neuroendocrine cell-specific transcription factors (ASCL1, BRN2), a proliferation marker (Ki-67 labeling index), and an oncogene (NF1B). Formalin-fixed and paraffin-embedded sections of SCLC tumors were subjected to immunohistochemistry and quantitative reverse-transcription polymerase chain reaction analyses. In a case-control cohort matched for basic clinical factors, expression of ProGRP, synaptophysin, chromogranin A, and ASCL1 was significantly decreased in TTF-1-negative SCLC samples. In contrast, there was no significant correlation between Ki-67 labeling index and TTF-1. In a larger serial case cohort, TTF-1-negative SCLC cases were older at diagnosis, but there was no significant difference in the overall survival of patients with TTF-1-negative and TTF-1-positive SCLC. In conclusion, TTF-1-negative SCLC showed decreased neuroendocrine differentiation, and significantly worse clinical outcomes were not observed. | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Limitations in obtaining surgically resected or biopsy samples of small cell lung cancer (SCLC) tumors make comprehensive biological analyses difficult. The loss of thyroid transcription factor 1 (TTF-1) has been associated with the aggressive behavior of non-small cell lung cancer; however, clinicopathological features of TTF-1-negative SCLC remain unclear. This study aimed to elucidate the characteristics of TTF-1-negative SCLC. We studied the associations between the expression of TTF-1 and the clinicopathological factors associated with SCLC, including survival and expression of neuroendocrine markers (synaptophysin, chromogranin A, and CD56), neuroendocrine cell-specific transcription factors (ASCL1, BRN2), a proliferation marker (Ki-67 labeling index), and an oncogene (NF1B). Formalin-fixed and paraffin-embedded sections of SCLC tumors were subjected to immunohistochemistry and quantitative reverse-transcription polymerase chain reaction analyses. In a case-control cohort matched for basic clinical factors, expression of ProGRP, synaptophysin, chromogranin A, and ASCL1 was significantly decreased in TTF-1-negative SCLC samples. In contrast, there was no significant correlation between Ki-67 labeling index and TTF-1. In a larger serial case cohort, TTF-1-negative SCLC cases were older at diagnosis, but there was no significant difference in the overall survival of patients with TTF-1-negative and TTF-1-positive SCLC. In conclusion, TTF-1-negative SCLC showed decreased neuroendocrine differentiation, and significantly worse clinical outcomes were not observed. | |||||
書誌情報 |
en : Human pathology 巻 79, p. 127-134, 発行日 2018 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1532-8392 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 29787820 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1016/j.humpath.2018.05.009 |